Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $26.0 million.

  • Nurix Therapeutics' Current Deferred Revenue fell 45.84% to $26.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $26.0 million, marking a year-over-year decrease of 45.84%. This contributed to the annual value of $38.4 million for FY2024, which is 20.24% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Current Deferred Revenue of $26.0 million as of Q3 2025, which was down 5.20% from $27.4 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Current Deferred Revenue ranged from a high of $48.1 million in Q4 2023 and a low of $26.0 million during Q3 2025.
  • Over the past 3 years, Nurix Therapeutics' median Current Deferred Revenue value was $38.4 million (recorded in 2024), while the average stood at $38.7 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 49.82% in 2024, then plummeted by 45.84% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Current Deferred Revenue (Quarterly) stood at $41.2 million in 2021, then declined by 8.68% to $37.6 million in 2022, then increased by 27.81% to $48.1 million in 2023, then dropped by 20.24% to $38.4 million in 2024, then crashed by 45.84% to $26.0 million in 2025.
  • Its Current Deferred Revenue stands at $26.0 million for Q3 2025, versus $27.4 million for Q2 2025 and $30.6 million for Q1 2025.